Sebastian Pistritto, chief marketing officer at ParcelShield Holdings, LLC, talks about how technology such as artificial intelligence helps to evaluate data to assist in medication delivery service decision-making, depending on the need of the pharmacy and its patients.
Technology such as artificial intelligence can analyze performance delivery data to to help medication delivery service decision-making, depending on the need of the pharmacy and its patients, explains Sebastian Pistritto, chief marketing officer at the ParcelShield Holdings, LLC.
Transcript
What technology advancements have been effective at medication delivery?
I would say 2 things: there's much more rich data today available in the market, and there's also technology that can help you to access that data. That data is really performance delivery data that is across the carriers so that you have the ability to understand historically, what level of delivery performance has been successful in delivering patient medication on time.
How can data analytics and artificial intelligence be utilized to optimize medication delivery performance?
There's a lot of data out in the market today. The way artificial intelligence plays a part in that [is] it helps to really decipher all that data. Imagine 20 years’ worth of delivery performance data, whether it's the post office, whether it's UPS or whether it's FedEx, and the multiple different delivery services across all the homes and all the zip codes and all the states that this medication has to be delivered. Artificial Intelligence provides the ability to decipher through all that data and help us to make better decisions. “Well, which delivery method is better for my pharmacy? What is the optimum day to deliver that medication? How successful has a particular service level been in the past? Which carrier should I select in order to make sure that I am successful in making that delivery directly to the patient?”
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More